INVESTOR RELATIONS

Please Contact David Schull for further information

David Schull
Russo Partners
212.845.4271
david.schull@russopartnersllc.com

November 10, 2008
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera’s Relaxin in Acute Heart Failure

November 03, 2008
Top-Line Preliminary Data From Phase II/III Study of Corthera’s Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008

January 08, 2008
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure

December 20, 2007
Corthera Closes $23 Million Financing Round